ArticleCancer & metabolism2025
Dexmedetomidine promotes colorectal cancer progression mediated by gamma-aminobutyric acid signaling.
Article in Cancer & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuron-tumor interplay in colorectal cancer: from mechanisms of onset and progression to targeted therapies.Cell communication and signaling : CCS · 2026Review
- Effect of intraoperative dexmedetomidine on prognosis in patients with cancer undergoing surgical procedures. Responses to recent commentary.British journal of anaesthesia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveCancer cells exhibit abnormal dependence on glutamine, which is associated with the hyperactivation of γ-aminobutyric acid (GABA) metabolic pathways that promotes tumor growth. The α2-adrenergic receptor agonist dexmedetomidine (DEX) has been reported to promote colorectal cancers (CRC) progression. However, the role of GABAergic signaling in DEX-induced tumorigenesis remains unclear.
methodsThis study analyzed clinical CRC specimens and The Cancer Genome Atlas (TCGA) to assess the expression of GABAB receptor subunit 1 (GABBR1) and its prognostic relevance. We measured neurotransmitter levels using ELISA and evaluated the expression of glutaminase 1 (GLS1), glutamate decarboxylase 1 (GAD1), GABBR1, and its subunit GB1e in CRC cell lines (RKO and SW480) using Western blotting. Cell proliferation, migration, and invasion were evaluated through Ki67 immunofluorescence, wound healing, and transwell assays. In vivo experiments were performed to evaluate the effect of DEX on tumor growth in CRC xenograft models.
resultsThe results revealed a significant increase in GABBR1 expression in human CRC tissues. DEX upregulated GLS1 and GAD1 expression in a dose-dependent manner, while also promoted GABA release and GB1e expression in CRC cell lines. Activated GABAergic signaling by DEX enhanced CRC cell proliferation, migration, and invasion, as well as tumor growth in vivo. Mechanistically, upregulated GB1e stabilized β-catenin expression by inhibiting Tyr216-p-GSK3β activity, thereby facilitating the epithelial-mesenchymal transition (EMT) process.
conclusionOur study demonstrated that DEX significantly increased GABA release and GB1e expression in CRC cells, leading to activation of GSK3β/β-catenin pathway and then EMT. These findings suggest that GABAergic signaling may contribute to DEX-induced tumor-promoting effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.